Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 16/20 | 0.64 |
| ▸ | CRBN | Q96SW2 | 16/20 | 0.64 |
| ▸ | NMT1 | P30419 | 3/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.34 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30043700 | 0.99 | DDB1 (0.63) | DDB1CRBNNMT1ITGB3ITGA2B | |
| SCHEMBL26635000 | 0.97 | DDB1 (0.63) | DDB1CRBNNMT1ITGB3ITGA2B | |
| SCHEMBL23832588 | 0.94 | CRBN (0.67) | DDB1CRBNIKZF3 | |
| Hydrochloric Acid SCHEMBL30893224 | 0.93 | CRBN (0.66) | DDB1CRBNIKZF3 | |
| Trifluoroacetic Acid SCHEMBL25340753 | 0.93 | DDB1 (0.57) | DDB1CRBNNMT1ITGB3ITGA2B | |
| SCHEMBL24764247 | 0.92 | CRBN (0.58) | DDB1CRBNNMT1 | |
| Hydrochloric Acid SCHEMBL30042846 | 0.91 | CRBN (0.57) | DDB1CRBNNMT1 | |
| SCHEMBL24765164 | 0.91 | CRBN (0.66) | DDB1CRBNIKZF3 | |
| SCHEMBL24764223 | 0.91 | DDB1 (0.58) | DDB1CRBNITGB3ITGA2B | |
| Hydrochloric Acid SCHEMBL30043401 | 0.90 | DDB1 (0.58) | DDB1CRBNITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20240293423-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-09-05 | — | — | US | disclosed |
| EP-4405359-A2 | MDM2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| US-20240059674-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-02-22 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| EP-4225303-A1 | STAT DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2023049790-A2 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-03-30 | — | — | WO | disclosed |
| US-20230069104-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-11-10 | — | — | US | disclosed |
| EP-3989966-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| WO-2022077010-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTIC, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2020264499-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020264499-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | DDB1 511/4885CRBN 39/4885NMT1 3858/4885 |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK4 | DDB1 2480/4885CRBN 79/4885NMT1 4077/4885 |
| US-20240059674-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | DDB1 1267/4885CRBN 187/4885NMT1 3976/4885 |
| US-20230069104-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK4, IRAK2, IRAK3 | DDB1 68/4885CRBN 322/4885NMT1 3256/4885 |
| US-20220356185-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, ITK, CRKL | DDB1 3837/4885CRBN 183/4885NMT1 708/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | DDB1 1267/4885CRBN 187/4885NMT1 3976/4885 |
| US-20240293423-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | DDB1 3993/4885CRBN 171/4885NMT1 3525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.